Steve Bryson, PhD,  science writer—

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Test for Cushing’s still performs well with limited measurements

Limiting the number of measurements in the low-dose overnight dexamethasone suppression test (oDST), which is commonly used to diagnose Cushing’s syndrome, does not affect the test’s performance, a study showed. A new protocol, called Reflex, performs additional tests only among people whose initial tests suggest the presence of Cushing’s.

Skin cream deemed cause of woman’s Cushing’s syndrome

Long-term use of topical corticosteroids for a genetic skin condition caused Cushing’s syndrome and adrenal insufficiency — low hormone production from the adrenal glands — in a 50-year-old woman, according to a case report. “This case highlights the risk of systemic complications from chronic topical corticosteroid use,” the researchers wrote.

Using noninvasive test combo can correctly distinguish Cushing’s

A combination of two noninvasive tests — the dexamethasone suppression test and high-resolution MRI scans — was found to correctly distinguish between Cushing’s disease and ectopic Cushing’s syndrome in patients, according to a new study. The accuracy seen in combining these tests was comparable to that of bilateral inferior…

2 women with Cushing’s disease use metyrapone throughout pregnancy

Two women with Cushing’s disease successfully used the cortisol-lowering medication metyrapone during their pregnancy, a case study shows. “Metyrapone represents a viable option for managing [Cushing’s disease] throughout pregnancy when surgical intervention is contraindicated or declined, although careful monitoring and dose optimization are essential,” the researchers wrote. The cases…

Signifor effective in half of Cushing’s disease patients: Study

Treatment with Signifor (pasireotide) normalized urinary cortisol levels in about half of adults with Cushing’s disease, regardless of their gender, a small real-world study suggests. Because treatment response was associated with the absence of diabetes before treatment, researchers suggest proper blood sugar management in patients planning to start…

Case report: Rare PPNAD Cushing’s caused by gene duplication

An 8-year-old girl was diagnosed with primary pigmented nodular adrenocortical disease (PPNAD), a rare genetic disorder that can cause Cushing’s syndrome, a case study reports. Hers was the first reported case of PPNAD caused by a duplication in the PRKACA gene. according to the researchers. The girl’s case was described in…